FirstLook Lung, a blood test that offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT with a negative predictive value of 99.7%, was commercially introduced.
Circulating tumor DNA has the potential to not only change the way medical oncologists assess and treat cancer patients, but also how cancer drugs are reviewed, oncology experts at FDA and pharmaceutical companies said in response to research findings published July 11 by a collaboration led by Friends of Cancer Research.
Patients with metastatic non-small cell lung cancer who are matched to targeted therapy live longer when liquid biopsies are used to detect genomic alterations in circulating tumor DNA that aren’t picked up by tissue sequencing, according to a study published Nov. 10 in Nature Medicine.
FDA granted marketing authorization to the Parsortix System for the harvesting of circulating cancer tumor cells in metastatic breast cancer.
Myriad Genetics Inc. expanded its partnership with Intermountain Precision Genomics to add a new liquid biopsy therapy selection test to its oncology portfolio.
NCI has issued a Request for Information seeking input from developers of multi-cancer early detection liquid biopsy tests, with the goal of launching an NCI-sponsored randomized controlled screening clinical trial of these tools.
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers.
